Current prospects for improving the quality of life of patients with internal stents


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Internal drainage of the upper urinary tract by stenting is a common urological procedure. The use of stenting in modern urological practice is on the rise due to widespread adoption of modern endourological, laparoscopic, percutaneous and high-tech robotic interventions. The presence of a stent in the patient’s body may cause stent-related symptoms and negatively affect the quality of life, resulting in additional outpatient visits and hospitalizations. The review provides an analysis of the causes, diagnostic evaluation, prevention and treatment of stent-related symptoms. The authors describe the management options including a-blockers, anticholinergics, and their combinations.

Full Text

Restricted Access

About the authors

A. G Martov

A.I. Burnazyan SSC Federal Medical Biophysical Center of FMBA of Russia; City Clinical Hospital №57

Email: martovalex@maiI.ru
Dr.Med.Sci., Prof., Head of Department of Minimally Invasive Methods of Diagnosis and Treatment of Urologie Diseases «MMDiF», D.D. Pletnev CCH, Moscow HD; Head of Department of Urology and Andrology, IPPE of A.I. Burnazyan SSC FMBC, FMBA of Russia

D. V Ergakov

A.I. Burnazyan SSC Federal Medical Biophysical Center of FMBA of Russia; City Clinical Hospital №57

Ph.D., Urologist at the Department of Minimally Invasive Methods of Diagnosis and Treatment of Urologie Diseases «MMDiF», D.D. Pletnev CCH, Moscow HD; Associate Professor at Department of Urology and Andrology, IPPE of A.I. Burnazyan SSC FMBC, FMBA of Russia

A. B Novikov

Multidisciplinary Medical Center of the Bank of Russia

Head of the Urology Department

References

  1. Зенков С.С. Внутреннее дренирование верхних мочевыводящих путей. Дисс. к.м.н., 1998 г.
  2. Мартов А.Г., Ергаков Д.В., Корниенко С.И., Абоян И.А., Павлов С.В., Асфандияров Ф.Р., Калашников Е.С. Улучшение качества жизни больных с внутренними стентами путем изменения их формы. Урология. 2011;2:7-13
  3. Мартов А.Г., Максимов В.А., Ергаков Д.В., Мирошников В.М., Асфандияров Ф.Р., Калашников Е.С. Применение тамсулозина в профилактике и лечении стентзависимых симптомов. Урология. 2010;1:3-8
  4. Hao P., Li W., Song C., Yan J., Song B., Li L. Clinical Evaluation Of Double-Pigtail in Patients with Upper Urinary Tract Diseases: Report of 2685 cases. J. Endourol. 2008;22:65-70.
  5. Ho C.H., Chen S.C., Chung S.D., Lee Y.J., Chen J., Yu H.J., Huang K.H. Determining the Apropriate Length of a Double-Pigtail Ureteral Stent by Both Stent Configurations and Related Symptoms. J. Endourol. 2008;22:1427-1431.
  6. Joshi H.B., Newns N., Stainthorpe A., MacDonagh R.P., Keeley F.X. Jr, Timoney A.G. Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure. J. Urol. 2003;169:1060-1064.
  7. Borboroglu P.G., Amling C.L., Schenkman N.S., Monga M., Ward J.F., Piper N. Y., Bishoff J. T., Kane C.J. Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi-institutional prospective randomized controlled study assessing pain, outcomes and complications. J. Urol. 2001;166:1651-1657.
  8. Lee C., Kuskowski M., Premoli J., Skemp N., Monga M. Randomized evaluation of Ureteral Stents using validated Symptom Questionnaire. J. Endourol. 2005;19:990-993.
  9. Hruby G.W., Ames C.D., Yan Y., Monga M., Landman J. Correlation of ureteric length with anthropometric variance of surface body habitus. BJU Int. 2007;99:1119-1122.
  10. Mendez-Probst C.E., Goneau L.W., MacDonald K.W., Nott L., Seney S., Elwood C.N., Lange D., Chew B.H., Denstedt J.D., Cadieux P.A. The use of triclosan eluting stents effectively reduces ureteral stent symptoms: A prospective randomized trial. BJU Int. 2012;110:749-754.
  11. Vanderbrink B.A., Rastinehead A.R., Ost M.C., Smith A. Encrusted Urinary Stents: Evaluation and Endourologic Management. J. Endourol. 2008;22:905-912.
  12. Riedl C.R., Witkowski M., Plas E., Pflueger H. Heparin coating reduces encrustation of ureteral stents: A preliminary report. Int J. Antimicrob Agents. 2002;19:507-510.
  13. Liatsikos E.N., Hom D., Dinlenc C.Z., Kapoor R., Alexianu M., Yohannes P., Smith A.D. Tail Stent versus reentry tube: A randomized comparison after percutaneous stone extraction. Urology 2002;59:15-19.
  14. Beiko D.T., Knudsen B.E., Denstedt J.D. Advances in Ureteral Stent Design. J. Endourol. 2003;17:195-199.
  15. Dunn M.D., Portis A.J., Kahn S.A., Yan Y., Shalhav A.L., Elbahnasy A.M., Bercowsky E., Hoenig D.M., Wolf J.S. Jr, McDougall E.M., Clayman R.V. Clinical effectiveness of new stent design: Randomized single-blind comparison of tail and double pig-tail stents. J. Endourol. 2000;14:195-202.
  16. Damiano R., Autorino R., De Sio M., Cantiello F., Quarto G., Perdonà S., Sacco R., DArmiento M. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol. 2005;48:673-678.
  17. Beiko D.T., Watterson J.D., Knudsen B.E., Nott L., Pautler S.E., Brock G.B., Razvi H., Denstedt J.D. Double-blind Randomized Control Trial Assessing the Safety and Efficacy of Intravesical Agents for Ureteral Stent Symptoms after Extracorporeal Shockwave Lithotripsy. J. Endourol. 2004; 18:723-730.
  18. Gupta M., Patel T., Xavier K., Maruffo F., Lehman D., Walsh R., Landman J. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J. Urol. 2010;183:598-602.
  19. Deliveliotis C., Chrisofos M., Gougousis E., Papatsoris A., Dellis A., Varkarakis I.M. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67:35-39.
  20. Dellis A.E., Keeley F.X. Jr, Manolas V., Skolarikos A.A. Role of a-blockers in the treatment of stent-related symptoms: A prospective randomized control study. Urology. 2014;83:56-61.
  21. Wang C.J., Huang S.W., Chang C.H. Effects of specific alpha1A/1D blocker on lower urinary tract symptoms due to double-J stent: A prospectively randomized study. Urol Res. 2009;37:147-152.
  22. Lee Y.J., Huang K.H., Yang H.J., Chang H.C., Chen J., Yang T.K. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41:247-252.
  23. El-Nahas A.R., Tharwat M., Elsaadany M., Mosbah A., Gaballah M.A. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J. Urol. 2016;34:963-968.
  24. Lim K.T., Kim Y.T., Lee T.Y., Park S.Y. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent-related discomforts. Korean J. Urol. 2011;52: 485-488.
  25. Park J., Yoo C., Han D.H., Shin D.W. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stentrelated symptoms: A 2.2 factorial randomized trial. World J. Urol. 2015;33:1833-1840.
  26. Park S.C., Jung S.W., Lee J.W., Rim J.S. The Effects of Tolterodine ER and Alfuzosin for the Treatment of Double-J Stent-Related Symptoms. J. Endourol. 2009;23:1913-1917.
  27. Tehranchi A., Rezaei Y., Khalkhali H., Rezaei M. Effects of Terazosin and Tolterodine on ureteral stent related symptoms: A double-blind placebo-controlled randomized clinical trial. Int Braz J. Urol. 2013;39:832-840.
  28. Sivalingam S., Streeper N.M., Sehgal P.D., Sninsky B.C., Best S.L., Nakada S.Y. Does combination therapy with tamsulosin and tolterodine improve ureteral stent discomfort compared with tamsulosin alone? A double-blind, randomized, controlled trial. J. Urol. 2016;195:385-390.
  29. Zhou L., CaiX., Li H., Wang K.J. Effects of a-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: A meta-analysis. J. Endourol. 2015;29:650-656.
  30. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., DAngelo K. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J. Am Geriatr Soc. 1998;46:8-13.
  31. Мартов А.Г., Максимов В.А., Ергаков Д.В., Давыдова С.С., Асфандияров Ф.Р., Калашников Е.С. Применение толтеродина в лечении смптомов, связанных с наличием у пациентов внутреннего стента. Уральский медицинский журнал. 2012;2(94):18-26

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies